Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.08 USD | -3.39% | -5.27% | +55.98% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 800K | Capitalization | 659M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -241M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 824 x |
P/E ratio 2024 * |
-4.19
x | P/E ratio 2025 * |
-2.85
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | -3.39% | ||
1 week | -5.27% | ||
Current month | +59.03% | ||
1 month | +58.15% | ||
3 months | +58.44% | ||
6 months | +80.74% | ||
Current year | +55.98% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 28 M€ | -1.80% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 17.08 | -3.39% | 525,910 |
24-05-24 | 17.68 | +0.80% | 455,763 |
24-05-23 | 17.54 | -1.79% | 388,984 |
24-05-22 | 17.86 | -0.94% | 321,431 |
24-05-21 | 18.03 | -0.33% | 480,197 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.98% | 659M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- ITOS Stock